Key result
Carney complex mutations amplify nonclassical PKA activation pathways, such as oligomerization-induced losses of PKA R1α inhibitory function, compared to wild-type and ACRDYS1 mutations.
Why the study?
Carney complex mutations are known to cause overactivation of PKA, but the molecular mechanisms underlying kinase overactivity in the context of canonical cAMP-dependent activation are not fully understood.
Familial mutations of the protein kinase A (PKA) R1α regulatory subunit lead to a generalized predisposition for a wide range of tumors, from pituitary adenomas to pancreatic and liver cancers, commonly referred to as Carney complex (CNC). CNC mutations are known to cause overactivation of PKA, but the molecular mechanisms underlying such kinase overactivity are not fully understood in the context of the canonical cAMP-dependent activation of PKA. Here, we show that oligomerization-induced sequestration of R1α from the catalytic subunit of PKA (C) is a viable mechanism of PKA activation that can explain the CNC phenotype. Our investigations focus on comparative analyses at the level of structure, unfolding, aggregation, and kinase inhibition profiles of wild-type (wt) PKA R1α, the A211D and G287W CNC mutants, as well as the cognate acrodysostosis type 1 (ACRDYS1) mutations A211T and G287E. The latter exhibit a phenotype opposite to CNC with suboptimal PKA activation compared with wt. Overall, our results show that CNC mutations not only perturb the classical cAMP-dependent allosteric activation pathway of PKA, but also amplify significantly more than the cognate ACRDYS1 mutations nonclassical and previously unappreciated activation pathways, such as oligomerization-induced losses of the PKA R1α inhibitory function.
No takes yet. Share an insight, caveat, or question.
Jafari et al. (2021) studied Carney complex. Carney complex mutations (A211D and G287W) vs. Wild-type PKA R1α and ACRDYS1 mutations was evaluated on PKA activation pathways and kinase inhibition profiles. Carney complex mutations amplify nonclassical PKA activation pathways, such as oligomerization-induced losses of PKA R1α inhibitory function, compared to wild-type and ACRDYS1 mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: